KR960002850B1 - (1r,5s,6s)-2-치환티오-6-[(r)-1-히드록시에틸]-1-메틸-카바페넴-3-카복실산 유도체 - Google Patents

(1r,5s,6s)-2-치환티오-6-[(r)-1-히드록시에틸]-1-메틸-카바페넴-3-카복실산 유도체 Download PDF

Info

Publication number
KR960002850B1
KR960002850B1 KR1019880004109A KR880004109A KR960002850B1 KR 960002850 B1 KR960002850 B1 KR 960002850B1 KR 1019880004109 A KR1019880004109 A KR 1019880004109A KR 880004109 A KR880004109 A KR 880004109A KR 960002850 B1 KR960002850 B1 KR 960002850B1
Authority
KR
South Korea
Prior art keywords
compound
formula
carbapenem
methyl
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019880004109A
Other languages
English (en)
Korean (ko)
Other versions
KR880012604A (ko
Inventor
도시오 구마가이
히로시 마쓰나가
요시스께 마찌다
유우노스께 나가세
마네오 히끼다
요시미쓰 나가오
Original Assignee
니혼 레다리 가부시끼가이샤
고니시 신베에, 히사나가 쇼오이찌로오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니혼 레다리 가부시끼가이샤, 고니시 신베에, 히사나가 쇼오이찌로오 filed Critical 니혼 레다리 가부시끼가이샤
Publication of KR880012604A publication Critical patent/KR880012604A/ko
Application granted granted Critical
Publication of KR960002850B1 publication Critical patent/KR960002850B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1019880004109A 1987-04-11 1988-04-11 (1r,5s,6s)-2-치환티오-6-[(r)-1-히드록시에틸]-1-메틸-카바페넴-3-카복실산 유도체 Expired - Fee Related KR960002850B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP89016/87 1987-04-11
JP69016/87 1987-04-11
JP8901687 1987-04-11
JP63031033A JPS6425779A (en) 1987-04-11 1988-02-15 (1r,5s,6s)-2-substituted-thio-6-((r)-1-hydroxyethyl)-1-methyl -carbapenem-3-carboxylic acid derivative
JP31033/88 1988-02-15

Publications (2)

Publication Number Publication Date
KR880012604A KR880012604A (ko) 1988-11-28
KR960002850B1 true KR960002850B1 (ko) 1996-02-27

Family

ID=26369486

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880004109A Expired - Fee Related KR960002850B1 (ko) 1987-04-11 1988-04-11 (1r,5s,6s)-2-치환티오-6-[(r)-1-히드록시에틸]-1-메틸-카바페넴-3-카복실산 유도체

Country Status (12)

Country Link
EP (1) EP0289801B1 (enExample)
JP (1) JPS6425779A (enExample)
KR (1) KR960002850B1 (enExample)
AU (1) AU613356B2 (enExample)
CA (1) CA1340274C (enExample)
DE (1) DE3860977D1 (enExample)
DK (1) DK168015B1 (enExample)
ES (1) ES2019674B3 (enExample)
FI (1) FI86729C (enExample)
GR (1) GR3001347T3 (enExample)
IL (1) IL85985A (enExample)
NO (1) NO167862C (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68916908T2 (de) * 1988-11-08 1994-12-01 Daiichi Seiyaku Co Carbapenemderivate.
US5102877A (en) * 1989-04-28 1992-04-07 Fujisawa Pharmaceutical Co., Ltd. 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds
JP2771637B2 (ja) * 1989-10-17 1998-07-02 シーアイ化成株式会社 作物栽培用被覆フイルム及びそれを用いる栽培方法
WO1991009860A1 (fr) * 1989-12-28 1991-07-11 Banyu Pharmaceutical Co., Ltd. Nouveau derive de carbapenem
US5227376A (en) * 1990-02-14 1993-07-13 Sumitomo Pharmaceuticals Co., Ltd. β-lactam compounds and their production
US5241073A (en) * 1990-10-12 1993-08-31 Lederle (Japan) Process for preparing (1R,5S,6S)-2-[(6,7-dihydro-5H-pyrazolo [1,2-a][1,2,4]triazolium-6-yl)]thio-6-[(R)-1-hydroxyethyl]-1-methyl-carbapenem-3-carboxylate and starting materials thereof
DE69028920T2 (de) * 1990-10-12 1997-02-13 Lederle Japan Ltd Verfahren zur Herstellung von (1R,5S,6S)-2-[(6,7-Dihydro-5H-pyrazolo[1,2-a][1,2,4]triazolium-6-yl)thio]-6-[(R)-1-hydroxyethyl]-1-methyl-carbapenem-3-Carbonsäureester und deren Ausgangsverbindungen
US5286721A (en) * 1990-10-15 1994-02-15 Fujisawa Pharmaceutical Co., Ltd. 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds
TW264475B (enExample) * 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
AU3648893A (en) * 1992-03-17 1993-10-21 Yamanouchi Pharmaceutical Co., Ltd. Carbapenem derivative
US5550229A (en) * 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
CA2268820A1 (en) * 1996-10-28 1998-05-07 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
JP2003517427A (ja) * 1997-09-09 2003-05-27 メルク エンド カムパニー インコーポレーテッド ３−（ヨードフェノキシメチル）カルバペネム系抗菌剤
KR100476672B1 (ko) * 2001-08-16 2005-03-17 한국과학기술연구원 티올 유도체 및 이를 치환기로 갖는 1-베타-메틸-카바페넴유도체
JP2008303143A (ja) * 2005-08-19 2008-12-18 Shionogi & Co Ltd 連続化反応によるカルバぺネム誘導体の製法
TW200815442A (en) 2006-04-28 2008-04-01 Kaneka Corp Improved method for the crystallization of intermediates of carbapenem antibiotics
CN103159789B (zh) * 2011-12-16 2015-11-25 四川科伦药物研究有限公司 一种比阿培南结晶体及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2961882D1 (en) * 1978-08-25 1982-03-04 Beecham Group Plc Beta-lactam anti-bacterials, compositions containing them and a process for their preparation
US4552873A (en) * 1981-08-19 1985-11-12 Sankyo Company Limited Carbapenem compounds, and compositions containing them
US4644061A (en) * 1982-09-28 1987-02-17 Bristol-Myers Company Carbapenem antibiotics
CA1273012A (en) * 1984-07-02 1990-08-21 Burton G. Christensen 1-methylcarbapenems having an externally alkylated mono- of bicyclic 2-quarternary heteroarylalkylthio substituent
DE3617626A1 (de) * 1986-05-26 1987-12-03 Bayer Ag Substituierte 6-hydroxymethyl-carbapenem-antibiotika, verfahren zu ihrer herstellung und ihre verwendung
FI91258C (fi) * 1988-04-01 1994-06-10 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten 2-(heterosyklyylitio)karbapeneemijohdannaisten valmistamiseksi

Also Published As

Publication number Publication date
JPH0438756B2 (enExample) 1992-06-25
ES2019674B3 (es) 1991-07-01
NO881534L (no) 1988-10-12
FI86729B (fi) 1992-06-30
IL85985A0 (en) 1988-09-30
AU613356B2 (en) 1991-08-01
FI881644A7 (fi) 1988-10-12
FI86729C (fi) 1992-10-12
KR880012604A (ko) 1988-11-28
DE3860977D1 (en) 1990-12-13
DK168015B1 (da) 1994-01-17
IL85985A (en) 1993-07-08
JPS6425779A (en) 1989-01-27
EP0289801B1 (en) 1990-11-07
NO881534D0 (no) 1988-04-08
EP0289801A1 (en) 1988-11-09
FI881644A0 (fi) 1988-04-08
DK192488D0 (da) 1988-04-08
DK192488A (da) 1988-10-12
NO167862C (no) 1991-12-18
CA1340274C (en) 1998-12-15
GR3001347T3 (en) 1992-08-31
NO167862B (no) 1991-09-09
AU1442888A (en) 1988-10-13

Similar Documents

Publication Publication Date Title
KR960002850B1 (ko) (1r,5s,6s)-2-치환티오-6-[(r)-1-히드록시에틸]-1-메틸-카바페넴-3-카복실산 유도체
US4866171A (en) (1R,5S,6S)-2-[(6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazolium-6-yl)]thio-6-[R-1-hydroxyethyl]-1-methyl-carbapenum-3-carboxylate
GB2104075A (en) Carbapenem derivatives, their preparation and compositions containing them
HU196800B (en) Process for producing carbepeneme derivatives and pharmaceutical compositions containing them as active component
CZ286878B6 (en) Carbapenems, process of their preparation, intermediates for their preparation, those carbapenems used for treating infections and pharmaceutical preparations
US5153188A (en) Piperidylthiocarbapenem derivatives
US6479478B1 (en) Carbapenem compounds
AU604949B2 (en) (1r,5s,6s)-2-substituted thio-6-{(r)-1-hydroxyethyl}-1-methyl-carbapenem-3- carboxylic acid derivatives
JP2654077B2 (ja) 結晶形態の１−メチル−カルバペネム化合物
JP2003183282A (ja) カルバペネム化合物
JP2003183281A (ja) カルバペネム化合物
JPS63255280A (ja) （１ｒ，５ｓ，６ｓ）−２−置換−６−〔（ｒ）−１−ヒドロキシエチル〕−１−メチル−カルバペネム−３−カルボン酸誘導体
HU198491B (en) Process for producing carbapenem antibiotics
JPS63255282A (ja) （１ｒ，５ｓ，６ｓ）−２−〔（チアゾリウム−２−イル）または（イミダゾリウム−２−イル）メチル〕チオ−６−〔（ｒ）−１−ヒドロキシエチル〕−１−メチル−カルバペネム−３−カルボキシレ−ト
JP2003183280A (ja) カルバペネム化合物
EP0358085A1 (en) (1R,5S,6S)-6-[(R)-1-Hydroxyethyl]-1-methyl-2-[(1-alkyl-1,2,4-triazolium-2-yl)alkyl]-thio-carbapenem-3-carboxylic acid derivatives
JPWO2000015640A1 (ja) カルバペネム化合物
JPH05255346A (ja) カルバペネム化合物
JPH07196660A (ja) ２−（ヘテロシクロアルケニルアルキル）チオカルバペネム誘導体
JPS63255283A (ja) （１ｒ，５ｓ，６ｓ）−２−〔（３−置換イミダゾリニウム−１−イル）アルキル〕チオ−６−〔（ｒ）−１−ヒドロキシエチル〕−１−メチル−カルバペネム−３−カルボキシレ−ト
JP2000086667A (ja) カルバペネム化合物
JPH0770139A (ja) ２−（モノ又はジ置換−６，７−ジヒドロ−５Ｈ−ピラゾロ［１，２−ａ］ピラゾリウム−６−イル）チオ−カルバペネム誘導体
JPWO1991009860A1 (ja) 新規なカルバペネム誘導体
JPH0730077B2 (ja) ６−アルキルチオ−カルバペネム誘導体
JPH0717977A (ja) （１ｒ，５ｓ，６ｓ）−２−［（４−置換−１，３−チアゾール−２−イル）アミノカルボニルメチルチオ］−６−［（ｒ）−１−ヒドロキシエチル］−１−メチル−カルバペン−２−エム−３−カルボキシレート

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20040127

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20050228

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20050228